The present invention relates to the field of medicine, particularly to novel uses of C-19 steroid compounds having an androsten-17-(OR4)-3-one structure for inhibiting angiogenesis and particularly the proliferation and/or migration of endothelial cells in the treatment of diseases involving a pathological neovascularization and/or excessive regenerative processes.